Table 4

Sequential administrations of PCV-13–PPV-23 among immunocompromised adults based on ACIP recommendation

Pneumococcal vaccine-naive immunocompromised* adult persons
 First vaccineInterval between two vaccinesSecond vaccine
PCV-13≥8 weeksPPV-23
Previously PPV-vaccinated immunocompromised adult persons ≥65 years
 First vaccineInterval between two vaccinesSecond vaccine
 PPV-23≥1 yearPCV-13
Previously received PPV-23 in immunocompromised adults, when aged <65 years
First vaccine before age 65Interval between first PPV-23 and PCV-13Second vaccineInterval between PCV-13 and second  PPV-23Third vaccine
PPV-23≥1 yearPCV-13≥8 weeksPPV-23
Interval between first and second PPV-23 vaccine: ≥5 years
  • *Immunocompromised conditions are defined as: congenital or acquired immunodeficiency, human immunodeficiency viral infection, chronic renal failure, nephrotic syndrome, leukaemia, lymphoma, Hodgkin disease, generalised malignancy, iatrogenic immunosuppression, solid organ transplant, multiple myeloma.

  • ACIP, Advisory Committee on Immunization Practices; PCV-13, pneumococcal conjugate vaccine with 13 serotypes; PPV-23, pneumococcal polysaccharide vaccine with 23 serotypes.